Noel Donnelly
Directeur Financier/CFO chez PEPGEN INC.
Fortune : - $ au 31/05/2024
Profil
Noel Donnelly is currently the Chief Financial Officer at PepGen Inc. Prior to this role, he served as the Chief Financial Officer at EIP Pharma, Inc. from 2019 to 2021.
Mr. Donnelly holds an MBA from Babson College and an undergraduate degree from the University of Massachusetts Lowell.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PEPGEN INC.
-.--% | 31/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Noel Donnelly
| Sociétés | Poste | Début |
|---|---|---|
| PEPGEN INC. | Directeur Financier/CFO | 01/10/2021 |
Anciens postes connus de Noel Donnelly
| Sociétés | Poste | Fin |
|---|---|---|
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Directeur Financier/CFO | 01/10/2021 |
Formation de Noel Donnelly
| Babson College | Masters Business Admin |
| University of Massachusetts Lowell | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Health Technology |
